Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. RHÖN-KLINIKUM AG
  6. News
  7. Summary
    RHK   DE0007042301

RHÖN-KLINIKUM AG

(RHK)
  Report
Delayed Xetra  -  11:36 2022-12-02 am EST
15.35 EUR   -0.32%
11/10Transcript : RHÖN-KLINIKUM Aktiengesellschaft, Nine Months 2022 Earnings Call, Nov 10, 2022
CI
11/10RHÖN-KLINIKUM AG closes first nine months of 2022 with revenue surplus
EQ
10/18Rhön-klinikum Aktiengesellschaft : Changes on the Board of Management
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

RHÖN-KLINIKUM AG closes first half of 2022 with increase in revenues

08/04/2022 | 02:02am EST

DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Half Year Results/Miscellaneous
RHÖN-KLINIKUM AG closes first half of 2022 with increase in revenues

04.08.2022 / 08:00
The issuer is solely responsible for the content of this announcement.


 

Corporate News

Bad Neustadt a. d. Saale | 4 August 2022

 

RHÖN-KLINIKUM AG closes first half of 2022 with increase in revenues

 

The first half of financial year 2022 was marked by the impacts of the COVID-19 pandemic and the geopolitical risks brought about by the war in Ukraine. The course of the pandemic prevented a return to normal due to the restrictions in the provision of services and medical staff on sick-leave.

The geopolitical developments culminated in a disruption in supply chains and an accompanying general rise in price levels. Whereas the Group subsidiaries of RHÖN-KLINIKUM AG were for the most part able to offset direct price increases in the area of energy thanks to delivery quantities contracted in the past, price increases with suppliers put a greater burden on the result. In the view of the Board of Management of RHÖN-KLINIKUM AG, the discord between the statutory reimbursement mechanisms on the one hand and the inflationary price trend on the other will end up having a considerable impact on the German healthcare industry. The Group therefore sees the very urgent need to quickly adjust the existing state base rates and other remuneration components to the current price level, also against the backdrop of the expired reimbursements in connection with the COVID-19 pandemic and calls on politicians to act promptly.

Dr Christian Höftberger, Chairman of the Board of Management of RHÖN-KLINIKUM AG, said: “Once again, the pandemic and the war in Europe is confronting us with extraordinary tasks. Looking forward, we are confident that we will continue our success in dealing with the related challenges, in particular the economic effects.”

We treated 427,344 patients in our hospitals and medical care centres in the first half of 2022, with the Group of RHÖN-KLINIKUM AG generating revenues of € 711.2 million, an EBITDA of € 52.8 million and a consolidated profit of € 12.8 million.

The COVID-19 pandemic completely laid bare the shortcomings in the existing healthcare policy with regard to investment funding. Contrary to the dual financing principle, such funding has not been made available to hospitals to a sufficient extent over the decades. This culminated in a chronic underfunding of the healthcare system.

RHÖN-KLINIKUM AG in principle welcomes the planned shift of certain hospital services to the outpatient area. At the same time, measures of the German legislator to significantly improve outpatient remuneration and additional investment funding to create further outpatient structures are required.

The measures restricting eligible professional groups set out in the draft of the Act to Stabilise the Finances of the Statutory Health Insurance Funds (SHIs) (GKV-Finanzstabilisierungsgesetz) are viewed critically. For hospitals it is stipulated that from 2024 only the nursing staff costs of certified nurses employed directly in the area of patient care on wards having their own beds will be eligible for inclusion in the nursing budget. This far too narrow interpretation fails to recognise the current labour market situation and is an obstacle to reducing the workload on nursing staff.

The Group also takes the view that the structure of the planned introduction of a defined measurement of the staffing levels according to the hospitals’ need (Pflegepersonalregelung 2.0 or PPR 2.0) in its current form is not suitable to relieve the workload on nursing staff and improve the quality of nursing. Rather, this provision is expected to create additional bureaucratic burdens in terms of a daily classification of nursing staff and an accompanying additional burden on nursing staff.

In June 2022, RHÖN-KLINIKUM AG terminated the agreement on the implementation of the white paper for the further development of university medicine (Zukunftspapier für die Weiterentwicklung der hessischen Universitätsmedizin) from 2017 between the Federal State of Hesse, Giessen and Marburg Universities including the related faculties of medicine, and Universitätsklinikum Gießen und Marburg (UKGM) observing the stipulated notice period. Not doing this would have meant the automatic renewal of the agreement for a further year.

The Board of Management of RHÖN-KLINIKUM AG welcomes the first steps towards normalisation in investment funding set out in the Letter of Intent (LoI) agreed with the Federal State of Hesse, but points out that contemplated investment funding, which, however, is still too low compared with other university hospitals, has to be supported by additional own funds. The general environment has changed significantly since the LOI was signed. Current developments are becoming more acute by the need to quickly overhaul the German healthcare system that has to be made more digital, put greater emphasis on the outpatient sector and be more resilient to crises.

The Board of Management of RHÖN-KLINIKUM AG continues to be interested in a follow-on agreement. “But to make Universitätsklinikum Gießen und Marburg GmbH well prepared for the future as well, we need not just a commitment in the long term but also a greater range of response options.” Dr Christian Höftberger emphasised.

Full results are published in the Quarterly Statement at:

https://en.rhoen-klinikum-ag.com/investor-relations/publications/interim-reports-quarterly-statements.html
 

 

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 846,000 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs around 18,200 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com

 

Contact:

RHÖN-KLINIKUM AG | Head of Investor Relations and Treasury
Julian Schmitt | T. +49 9771 65-12250 | julian.schmitt@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale

 



04.08.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a.d.Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 1413007

 
End of News DGAP News Service

1413007  04.08.2022 

fncls.ssp?fn=show_t_gif&application_id=1413007&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about RHÖN-KLINIKUM AG
11/10Transcript : RHÖN-KLINIKUM Aktiengesellschaft, Nine Months 2022 Earnings Call..
CI
11/10RHÖN-KLINIKUM AG closes first nine months of 2022 with revenue surplus
EQ
10/18Rhön-klinikum Aktiengesellschaft : Changes on the Board of Management
EQ
08/04RHÖN-KLINIKUM Aktiengesellschaft Reports Earnings Results for the Second Quarter and Si..
CI
08/04RHÖN-KLINIKUM AG closes first half of 2022 with increase in revenues
EQ
05/12RHÖN-KLINIKUM Aktiengesellschaft Reports Earnings Results for the First Quarter Ended M..
CI
05/12Rhön-klinikum Aktiengesellschaft : Financial year 2022 again marked by COVID-19 pandemic
EQ
05/08Rhön-klinikum Aktiengesellschaft : The Board of Management of RHÖN-KLINIKUM AG considers t..
EQ
03/24RHÖN-KLINIKUM Aktiengesellschaft Reports Earnings Results for the Full Year Ended Decem..
CI
03/24RHÖN-KLINIKUM AG looks back on successful financial year 2021
EQ
More news
Analyst Recommendations on RHÖN-KLINIKUM AG
More recommendations
Financials
Sales 2022 1 455 M 1 526 M 1 526 M
Net income 2022 16,9 M 17,7 M 17,7 M
Net Debt 2022 28,1 M 29,5 M 29,5 M
P/E ratio 2022 61,4x
Yield 2022 -
Capitalization 1 028 M 1 077 M 1 077 M
EV / Sales 2022 0,73x
EV / Sales 2023 0,70x
Nbr of Employees 18 137
Free-Float 7,69%
Chart RHÖN-KLINIKUM AG
Duration : Period :
RHÖN-KLINIKUM AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RHÖN-KLINIKUM AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 15,35 €
Average target price 15,00 €
Spread / Average Target -2,28%
EPS Revisions
Managers and Directors
Tobias Kaltenbach Chief Executive Officer
Stefan Stranz Chief Financial Officer
Jan Liersch Chairman-Supervisory Board
Gunther K. Weiß Chief Operating Officer
Georg Schulze-Ziehaus First Deputy Chairman-Supervisory Board